Cencora, Inc.

Health Care
Other Pharmaceuticals
www.cencora.com

Earnings Score
Safety Score

Market Cap $46.93B
PE 31
Debt $4.96B
Cash $3.30B
EV $48.60B
FCF $3.00B

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$1.51B
EBIT	$2.18B
ROE	192%
ROA	3%
FCF	$3.00B
Equity	$786.74M
Growth Stability	-361%
PE	31.1
PEG	3.43
PB	59.65
P/FCF	15.66
P/S	0.16
Price/Cash	0.07
Debt/Equity	6.31
Debt/FCF	1.66
Net Margins	1%
Gross Margins	3%
Op. Margins	1%
Earnings CAGR	6%
Sales Growth YoY	15%
Sales Growth QoQ	6%
Sales CAGR	9%
FCF CAGR	6%
Equity CAGR	-13%
Earnings Stability	0.23
Earnings Growth YoY	-99%
Earnings Growth QoQ	-99%

Earnings CAGR 5Y	9%
Sales CAGR 5Y	11%
FCF CAGR 5Y	16%
Equity CAGR 5Y	-23%
Earnings CAGR 3Y	10%
Sales CAGR 3Y	10%
FCF CAGR 3Y	16%
Equity CAGR 3Y	55%
Market Cap	$46.93B
Revenue	$293.96B
Dividend Yield	1%
Payout Ratio	28%
Assets	$67.10B
Total Debt	$4.96B
Cash	$3.30B
Shares Outstanding	194.94M
EV	48.6B
Earnings Score	10%
Safety Score	47%
Working Capital	-6.56B
Current Ratio	0.88
Gross Profit	$9.91B
Shares Growth 3y	-2%
Equity Growth QoQ	-26%
Equity Growth YoY	18%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale company that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. They provide drug distribution and consulting related to medical business operations and patient services. They also distribute a line of brand name and generic pharmaceuticals, over-the-counter (OTC) health care products and home health care supplies and equipment to health care providers throughout the United States, including acute care hospitals and health systems, independent and chain retail pharmacies, mail-order facilities, physicians, clinics and other alternate site facilities, as well as nursing and assisted living centers. They also provide pharmaceuticals and pharmacy services to long-term care, workers' compensation and specialty drug patients.

SEC Filings

Direct access to Cencora, Inc. (COR) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-Q Dec 31
- 10-K Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-Q Dec 31
- 10-K Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Cencora, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Cencora, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 6%

Stability 23%

loading chart...

Cencora, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Cencora, Inc..

Years

Calculation mode

= $46B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$3B	$3.2B	$3.4B	$3.6B	$3.8B	$4.1B	$4.3B	$4.6B	$4.9B	$5.2B	$5.6B	$56B
DCF		$2.9B	$2.8B	$2.7B	$2.6B	$2.5B	$2.4B	$2.4B	$2.3B	$2.2B	$2.1B	$21B
Value	$46B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	09/2015	09/2016	09/2017	09/2018	09/2019	09/2020	09/2021	09/2022	09/2023	09/2024	TTM
Net Margins	-0%	1%	0%	1%	0%	-2%	1%	1%	1%	1%	1%
ROA	-	5%	3%	4%	3%	-12%	4%	4%	4%	3%	3%
ROE	-	67%	18%	53%	29%	406%	264%	2K%	260%	192%	192%

Bad Net Margins (0.51%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	09/2015	09/2016	09/2017	09/2018	09/2019	09/2020	09/2021	09/2022	09/2023	09/2024	TTM
Debt over FCF	-	1.77	3.33	4.15	2.12	2.51	3.13	3.07	1.57	1.66	1.66
Debt over Equity	5.51	2.26	1.67	1.46	1.44	-5.5	11.95	95.03	8.15	6.31	6.31
Growth Stability	-	-	-	100%	75%	-361%	-	-	-	92%	-361%

Good Debt/FCF ratio (1.66)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Bad Debt/Equity ratio (6.31)

The company is overleveraged and has a bad balance between equity and debt.

Bad Graham’s Stability (-361%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	09/2015	09/2016	09/2017	09/2018	09/2019	09/2020	09/2021	09/2022	09/2023	09/2024	CAGR 5Y
Revenue YoY growth	-	8%	4%	10%	7%	6%	13%	11%	10%	12%	11%
Earnings YoY growth	-	-1K%	-74%	343%	-47%	-499%	-145%	8%	4%	-13%	9%
Equity YoY growth	-	236%	-3%	48%	-2%	-128%	-170%	-88%	835%	18%	-23%
FCF YoY growth	-	-26%	-62%	4%	89%	-10%	21%	-1%	56%	-13%	16%